Acute Myeloid Leukemia With Gene MutationsNCT03746912
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
A study testing Quizartinib Dihydrochloride in people with Acute Myeloid Leukemia With Gene Mutations, run by Daiichi Sankyo.
Trial summary
An expanded access program (EAP): Allows doctors to give medicine to patients, Before it is approved by health authorities. This EAP is for: Quizartinib Patients with FLT3-ITD mutated AML, AML that has come back, or Is resistant to other therapies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myeloid Leukemia With Gene Mutations
- What is being tested?
- Quizartinib Dihydrochloride
- Type of treatment
- Pill or oral medicine
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- Participants must satisfy all of the following inclusion criteria prior to receive treatment:
- Has provided written informed consent as approved per local regulations with privacy language in accordance with national regulations (eg, Health Insurance Portability and Accountability Act [HIPAA] authorization for US sites) prior to any protocol-related procedures
- Is 18 years of age or the minimum legal adult age (whichever is greater) at the time of informed consent
- Has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) or other myeloproliferative neoplasms (MPN), as defined by the World Health Organization (WHO) 2008 classification with ≥5% blasts in bone marrow, with or without extramedullary disease
- Is in relapse or refractory (R/R) to prior therapy, with or without HSCT
- Refractory is defined as:
Show all 18Show fewer
- participant did not achieve complete remission (CR), CR with incomplete platelet recovery (CRp), or CR with incomplete hematological recovery (CRi) under initial intensive therapy, or
- did not achieve CR, CRp, CRi, or partial remission (PR) under initial sufficient time course of treatment with hypomethylating agents or low-dose cytarabine (LoDAC)
- must have received at least one complete block of induction therapy seen as the optimum choice of therapy to induce remission or at least 4 cycles of therapy with a hypomethylating agent deemed sufficient to induce a response
- Relapse is defined as: relapse diagnosed by bone marrow assessment or by the appearance of peripheral blasts after the achievement of CR, CRp, or CRi, as defined by 2003 International Working Group criteria after AML therapy with or without consolidation or maintenance, and with or without HSCT
- Has documented FLT3-ITD mutation in bone marrow or peripheral blood in relation R/R disease
- Prior treatment with kinase inhibitors, including FLT3 targeted therapy or investigational FLT3 inhibitors is allowed
- Has an Eastern Cooperative Oncology Group (ECOG) performance score 0-3
- Discontinued prior AML treatment before the start of protocol treatment (except hydroxyurea or other treatment to control leukocytosis) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non-cytotoxic agents
- Has creatinine clearance >25 mL/min, as calculated with the Cockcroft-Gault formula
- Has serum potassium, magnesium, and calcium (serum calcium corrected for hypoalbuminemia) within institutional normal limits. Participants with electrolytes outside the normal range will be eligible if these values are corrected upon retesting following any necessary supplementation
- Total serum bilirubin ≤1.5 × upper limit of normal (ULN)
- Has serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 × ULN
Who cannot join
- Participants who meet any of the following criteria will be disqualified from enrollment:
- Is eligible to enroll in a recruiting clinical trial of quizartinib or is currently enrolled in an ongoing clinical trial of quizartinib
- Has previously participated in a randomized clinical study of quizartinib with an endpoint of survival that is not closed for efficacy
- Has acute promyelocytic leukemia (AML subtype M3)
- Has persistent, clinically significant ≥Grade 3 non-hematologic toxicity from prior AML therapy
- Has clinically significant acute graft-versus-host disease (GvHD) or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or ≥Grade 3 persistent or clinically significant non-hematologic toxicity related to HSCT
Show all 32Show fewer
- Has uncontrolled or significant cardiovascular disease, including:
- QTcF interval >450 ms
- Bradycardia of less than 50 beats per minute (bpm) unless the patient has a pacemaker
- Diagnosed or suspected long QT syndrome, or known family history of long QT syndrome
- History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes
- History of second or third degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers, and have no history of fainting or clinically relevant arrhythmia with pacemakers.
- Myocardial infarction within 6 months prior to screening
- Uncontrolled angina pectoris within 6 months prior to Screening
- New York Heart Association (NYHA) Class 3 or 4 congestive heart failure
- Left ventricular ejection fraction (LVEF) ≤45% or institutional lower limit of normal
- Uncontrolled hypertension
- Complete left bundle branch block
- Has active infection not well controlled by antibacterial, antifungal, and/or antiviral therapy
- Has active hepatitis B or C, or other active clinically relevant liver disease
- Is unwilling to receive infusion of blood products according to the protocol
- Women are regarded as of childbearing potential if they are not post-menopausal (at least 2 years without menses) or surgically sterile (at least 1 month before enrollment).
- Highly effective contraception methods include: combined (estrogen and progestogen containing) hormonal methods associated with inhibition of ovulation, intra-uterine device; surgical sterilization (including bilateral tubal occlusion, partner's vasectomy) or sexual abstinence if this is the preferred and usual lifestyle of the participant
- If a heterosexually active woman of childbearing potential:
- Either partner is unwilling or unable to use a highly effective contraceptive method (as described above) for the entire treatment period and for at least 6 months after the administration of the final dose of quizartinib
- Is unwilling to refrain from donating or retrieving ova for her own use from the time of Screening and throughout the treatment period, and for 12 weeks after the administration of the final dose of quizartinib
- Is pregnant - quizartinib should be permanently discontinued if pregnancy is confirmed
- Is unwilling to refrain from breastfeeding from the time of Screening and throughout the protocol period, and for 25 days after the administration of the final dose of quizartinib
- If a man whose sexual partner is a woman of childbearing potential:
- Either partner is unwilling or unable to use a highly effective contraceptive method (as described above) for the entire treatment period and for at least 6 months after completion of protocol treatment
- Is unwilling to refrain from freezing or donating sperm starting at Screening and throughout the treatment period and 105 days after the administration of the final dose of quizartinib
- Has any medical condition, serious intercurrent illness, or other circumstance that, in the treating physician's judgment, could jeopardize the participant's safety
About this study
Official title: An Open-Label, Multi-Center, Expanded Treatment Protocol of Quizartinib in Adult Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3-ITD Mutations
An expanded access program (EAP):
- Allows doctors to give medicine to patients,
- Before it is approved by health authorities.
This EAP is for:
- Quizartinib
- Patients with FLT3-ITD mutated AML,
- AML that has come back, or
- Is resistant to other therapies.
A participant will receive quizartinib if:
- The doctor submits a request,
- The participant is eligible, and
- The country allows the EAP.
Read the detailed description
This is an expanded access program (EAP) providing access to quizartinib for participants with Relapsed/Refractory FLT3-ITD mutated AML, prior to approval by local regulatory agencies. Availability of the EAP is dependent upon physician request, country eligibility and local/country regulations. EAP countries included Austria, Belgium, Brazil, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, and United States. Physicians may request access to the EAP for participants who they feel may benefit from quizartinib and meet the eligibility criteria.
Participants may continue quizartinib until there is a lack of clinical benefit or the occurrence of unacceptable toxicity. Treatment should be interrupted for allogeneic hematopoietic stem cell transplantation (HSCT), but may be resumed after the transplant.
Participant enrollment may continue until 18 months after regulatory approval, depending on country regulation; or until such time the marketed medication is available, whichever occurs first.
Participants will be asked to follow the care as outlined by their treating physician. Participants will be followed for 30 days after their final treatment or until the patient is transitioned to commercially available product. Physicians will be required to report safety data to Daiichi-Sankyo Inc.
Quizartinib is currently under development for the treatment of patients 18 years of age or older with relapsed (including after HSCT) or refractory FLT3-ITD mutated AML, and has been granted Fast Track Status in the US and an Orphan Drug Indication in the United States, Europe and Asia.
- Being tested
- Quizartinib Dihydrochloride
- Keywords
- Refractory or Relapsed, FLT3- internal tandem duplication (ITD) mutation, FLT3-ITD mutation
- Medical subject headings
- Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quizartinib DihydrochlorideDrug
Also called Quizartinib
Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myeloid Leukemia With Gene MutationsStudies of the same condition, open and under way.
- More trials run by Daiichi SankyoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Daiichi Sankyo
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03746912
- Sponsor's protocol ID
- AC220-A-U203
- Status last verified
- Apr 2020
- First submitted
- 15 Nov 2018
- Last updated
- 15 Apr 2020
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Multi-Center, Expanded Treatment Protocol of Quizartinib in Adult Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3-ITD Mutations
- ClinicalTrials.gov ID
- NCT03746912
- Acronym / sponsor ID
- AC220-A-U203
- Keywords
- Refractory or Relapsed, FLT3- internal tandem duplication (ITD) mutation, FLT3-ITD mutation
- Study type
- Expanded access
- Recruitment status
- No Longer Available
- Lead sponsor
- Daiichi SankyoIndustry (pharma, biotech, devices)
- First posted
- 20 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An expanded access program (EAP):
- Allows doctors to give medicine to patients,
- Before it is approved by health authorities.
This EAP is for:
- Quizartinib
- Patients with FLT3-ITD mutated AML,
- AML that has come back, or
- Is resistant to other therapies.
A participant will receive quizartinib if:
- The doctor submits a request,
- The participant is eligible, and
- The country allows the EAP.
Detailed description
This is an expanded access program (EAP) providing access to quizartinib for participants with Relapsed/Refractory FLT3-ITD mutated AML, prior to approval by local regulatory agencies. Availability of the EAP is dependent upon physician request, country eligibility and local/country regulations. EAP countries included Austria, Belgium, Brazil, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, and United States. Physicians may request access to the EAP for participants who they feel may benefit from quizartinib and meet the eligibility criteria.
Participants may continue quizartinib until there is a lack of clinical benefit or the occurrence of unacceptable toxicity. Treatment should be interrupted for allogeneic hematopoietic stem cell transplantation (HSCT), but may be resumed after the transplant.
Participant enrollment may continue until 18 months after regulatory approval, depending on country regulation; or until such time the marketed medication is available, whichever occurs first.
Participants will be asked to follow the care as outlined by their treating physician. Participants will be followed for 30 days after their final treatment or until the patient is transitioned to commercially available product. Physicians will be required to report safety data to Daiichi-Sankyo Inc.
Quizartinib is currently under development for the treatment of patients 18 years of age or older with relapsed (including after HSCT) or refractory FLT3-ITD mutated AML, and has been granted Fast Track Status in the US and an Orphan Drug Indication in the United States, Europe and Asia.
Study design
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Participants must satisfy all of the following inclusion criteria prior to receive treatment:
- Has provided written informed consent as approved per local regulations with privacy language in accordance with national regulations (eg, Health Insurance Portability and Accountability Act [HIPAA] authorization for US sites) prior to any protocol-related procedures
- Is 18 years of age or the minimum legal adult age (whichever is greater) at the time of informed consent
- Has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) or other myeloproliferative neoplasms (MPN), as defined by the World Health Organization (WHO) 2008 classification with ≥5% blasts in bone marrow, with or without extramedullary disease
- Is in relapse or refractory (R/R) to prior therapy, with or without HSCT
Key exclusion criteria (32 listed)
- Is eligible to enroll in a recruiting clinical trial of quizartinib or is currently enrolled in an ongoing clinical trial of quizartinib
- Has previously participated in a randomized clinical study of quizartinib with an endpoint of survival that is not closed for efficacy
- Has acute promyelocytic leukemia (AML subtype M3)
- Has persistent, clinically significant ≥Grade 3 non-hematologic toxicity from prior AML therapy
- Has clinically significant acute graft-versus-host disease (GvHD) or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or ≥Grade 3 persistent or clinically significant non-hematologic toxicity related to HSCT
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quizartinib DihydrochlorideAlso: QuizartinibTablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2020.
Related trials for Acute Myeloid Leukemia With Gene Mutations
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
Not yet recruitingPhase 1
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Acute Myeloid Leukemia, TP53 Gene Mutation
RecruitingObservational study
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Germline Mutation, Myelodysplastic Syndromes
Active, not recruitingPhase 1
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Not yet recruiting
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Quizartinib Dihydrochloride in people with Acute Myeloid Leukemia With Gene Mutations, run by Daiichi Sankyo.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2020.